Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone - Strekin

Next Previous
Drug Profile

Pioglitazone - Strekin

Alternative Names: Pioglitazone hydrochloride extended release tablet - Strekin; Pioglitazone hydrochloride thermogel - Strekin; Pioglitazone intratympanic gel - Strekin; STR 001; STR001 thermogel; STR001-ER; STR001-IT

Latest Information Update: 15 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Strekin
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hearing loss
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hearing loss

Most Recent Events

  • 06 Apr 2021 Pioglitazone is still in phase III trial for Hearing loss in Czech Republic, Germany, Switzerland and Poland (Intrataympanic) (PO) (EudraCT2017-000242-22) (NCT03331627)
  • 06 Feb 2020 Strekin completes the phase III RESTORE trial for Hearing loss in five European countries including Czech Republic, Germany, Switzerland and Poland (intrataympanic) (PO)(EudraCT2017-000242-22) (NCT03331627)
  • 12 Sep 2019 Strekin completes enrolment in the phase III RESTORE trial for Hearing loss in five European countries including Czech Republic, Germany, Switzerland and Poland (Intratympanic) (PO) (EudraCT2017-000242-22)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top